A RetroSearch Logo

Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Search Query:

Showing content from https://pubmed.ncbi.nlm.nih.gov/34217417/ below:

Impact of the suspension and restart of the Dutch breast cancer screening program on breast cancer incidence and stage during the COVID-19 pandemic

doi: 10.1016/j.ypmed.2021.106602. Epub 2021 Jun 30. Impact of the suspension and restart of the Dutch breast cancer screening program on breast cancer incidence and stage during the COVID-19 pandemic

Affiliations

Affiliations

Item in Clipboard

Impact of the suspension and restart of the Dutch breast cancer screening program on breast cancer incidence and stage during the COVID-19 pandemic

Anouk H Eijkelboom et al. Prev Med. 2021 Oct.

doi: 10.1016/j.ypmed.2021.106602. Epub 2021 Jun 30. Authors Anouk H Eijkelboom  1 , Linda de Munck  2 , Marc B I Lobbes  3 , Carla H van Gils  4 , Jelle Wesseling  5 , Pieter J Westenend  6 , Cristina Guerrero Paez  7 , Ruud M Pijnappel  8 , Helena M Verkooijen  9 , Mireille J M Broeders  10 , Sabine Siesling  11 ; NABON COVID-19 Consortium and the COVID and Cancer-NL Consortium Affiliations

Item in Clipboard

Abstract

The COVID-19 pandemic forced the Dutch national breast screening program to a halt in week 12, 2020. In week 26, the breast program was resumed at 40% capacity, which increased to 60% in week 34. We examined the impact of the suspension and restart of the screening program on the incidence of screen-detected and non-screen-detected breast cancer. We selected women aged 50-74, diagnosed during weeks 2-35 of 2018 (n = 7250), 2019 (n = 7302), or 2020 (n = 5306), from the Netherlands Cancer Registry. Weeks 2-35 were divided in seven periods, based on events occurring at the start of the COVID-19 pandemic. Incidence of screen-detected and non-screen-detected tumors was calculated overall and by age group, cT-stage, and cTNM-stage for each period in 2020, and compared to the incidence in the same period of 2018/2019 (averaged). The incidence of screen-detected tumors decreased during weeks 12-13, reached almost zero during weeks 14-25, and increased during weeks 26-35. Incidence of non-screen-detected tumors decreased to a lesser extent during weeks 12-16. The decrease in incidence was seen in all age groups and mainly occurred for cTis, cT1, DCIS, and stage I tumors. Due to the suspension of the breast cancer screening program, and the restart at reduced capacity, the incidence of screen-detected breast tumors decreased by 67% during weeks 9-35 2020, which equates to about 2000 potentially delayed breast cancer diagnoses. Up to August 2020 there was no indication of a shift towards higher stage breast cancers after restart of the screening.

Keywords: Breast cancer incidence; Breast cancer screening; COVID-19; Clinical tumor stage; cT-stage.

Copyright © 2021 Elsevier Inc. All rights reserved.

PubMed Disclaimer

Conflict of interest statement

The authors report no declarations of interest.

Figures

Fig. 1

Division of week 2–35 in…

Fig. 1

Division of week 2–35 in seven periods and the corresponding weeks.

Fig. 1

Division of week 2–35 in seven periods and the corresponding weeks.

Fig. 2

Average weekly incidence, overall (A)…

Fig. 2

Average weekly incidence, overall (A) and for screen-detected and non-screen-detected tumors (B) separately,…

Fig. 2

Average weekly incidence, overall (A) and for screen-detected and non-screen-detected tumors (B) separately, per 100.000 women aged 50–74 years living in the Netherlands at the start of the year. The following weeks in 2018 had 4 workings days instead of 5: week 14, 17, 19, and 21. The following weeks in 2019 had 4 working days instead of 5: week 17, 22, and 24. The following weeks in 2020 had 4 working days instead of 5: week 16, 18, 19, 21, and 23.

Fig. 3

Average weekly incidence over two…

Fig. 3

Average weekly incidence over two or three weeks, overall (A,B) and for screen-detected…

Fig. 3

Average weekly incidence over two or three weeks, overall (A,B) and for screen-detected (C,D) and non-screen-detected tumors (E,F) separately, per 100.000 women aged 50–74 years, stratified by cT-stage.

Fig. 4

Average weekly incidence over two…

Fig. 4

Average weekly incidence over two or three weeks, overall (A,B) and for screen-detected…

Fig. 4

Average weekly incidence over two or three weeks, overall (A,B) and for screen-detected (C,D) and non-screen-detected tumors (E,F) separately, per 100.000 women aged 50–74 years, stratified by cTNM-stage.

Similar articles Cited by References
    1. Brierley J.D., Gospodarowicz M.K., Wittekind C. 8th ed. Wiley-Blackwell; Oxford, UK: 2017. TNM Classification of Malignant Tumours.
    1. de Munck L., Fracheboud J., de Bock G.H., et al. Is the incidence of advanced-stage breast cancer affected by whether women attend a steady-state screening program? Int. J. Cancer. 2018;143(4):842–850. - PubMed
    1. Dinmohamed A.G., Cellamare M., Visser O., et al. The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands J. Hematol. Oncol. 2020;13(1):147. - PMC - PubMed
    1. Dinmohamed A.G., Visser O., Verhoeven R.H., et al. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. Lancet Oncol. 2020;21(6):750–751. - PMC - PubMed
    1. Eijkelboom A.H., de Munck L., Vrancken Peeters M., et al. Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study. J. Hematol. Oncol. 2021;14(1):64. - PMC - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3